Economic burden of type 2 diabetes management in France according to clinical characteristics
Authors' conclusion
The cost of treating patients with T2D is almost double that of controls without diabetes. However, the overall costs of treating diabetes in 2022 appear to be stable compared with 2013. Expanding access to new treatments and technologies could help improve clinical outcomes in T2D, potentially leading to reductions in costly complications. There is a need for improved health policies for people living with T2D in the overseas departments.
Study context
- Population
- Representative sample of adults in the French national healthcare system claims database, 2022; T2D mean age 68.4 years, 54.5% menmatched cohort
- Participants
- 80,127 vs 237,607
- Exposure
- Patients with T2D vs propensity-score-matched controls without diabetes
- T2Dn = 80,127
- Controlsn = 237,607reference
- Outcome
- Overall costs
- Follow-up
- 2022
Methodological detailsdescriptive, retrospective, propensity-score-matched controls, national healthcare claims database
- Descriptive
- Retrospective
- Propensity-score-matched controls
- National healthcare claims database
Main finding
As reported in the abstract
T2D
6614€
Controls
3797€
Observational data: associations, not effects.
Further findings
Overall costs in T2D: overseas departments vs metropolitan France
- Overseas departments vs metropolitan France
- 7210€ vs. 6484€
Treatment regimens among treated T2D patients
- Receiving diabetes treatment
- 66 891
- Insulin-containing regimens
- 20.3%
- Non-insulin monotherapy
- 40.0%
- Non-insulin dual therapy
- 24.8%
- Non-insulin triple therapy
- 13.0%
- GLP-1 RA prescribed
- 17.0%
Insulin use: overseas departments vs metropolitan France
- Overseas departments vs metropolitan France
- 25.5% vs. 20.0%
CGM prescriptions among treated patients · last quarter of 2022
- CGM prescribed
- 5.6%
- Of whom using insulin
- 94.0%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →